Indian Pharma Market - Top 50 Ranking for Sep-2014Anup Soans
Indian Pharma Market (IPM) Key Insights for Sep 2014: IPM grew by 578 Crores over Aug 2014 & 1227 Crs over Sep 2013.
The Seasonal spike seen in 2012 from July onwards, which peaks in Sep/Oct and comes down in Nov, was not observed last year due to DPCO / NLEM issues. Hence we are entering a phase where on low base of last year, the growth rates are expected to be in strong double digits for the next 3-4 months.
Source: AIOCD Pharmasofttech AWACS
Major Highlights for Month of July 2014: IPM clocked 7161 Crs in July 2014
Indian Pharma Market grew at 7.2% for the month of July 2010
For the month of July 2014, among the top 10, Sun Pharma grew by 14.2%, Lupin by 13.2% & Cipla at 9.5%
Macleods grew at 27.9% to be the 10th biggest corporate for the month of July 2014
With the Portfolio of Elder, Torrent is now placed at 16th rank in IPM.
24 co's have crossed the growth of IPM for the month of July 2014 among top 50
Among the top 50 Co's, Akumentis has the highest growth of 49.0% followed by Ajanta at 41.2% & Apex at 40.9%
16 Co's showed double digit growths among the top 50
Among the 11-20 ranked co's Macleods has the highest growth of 27.9% followed by Ipca at 21.2% & Aristo at 16.2%
Among the 51-60 ranked co's, Panacea grows at 36.9% followed by Troikaa at 22.3 & Systopic 20.3%
Among the 61-75 ranked co's, Lincoln grew at 43.7% followed by Corona at 36.3% & Serdia at 19.6%
Indian V/S MNCs:
Indian companies have grown at 9.1% versus 1.5% for MNCs in July 2014
Among the top 50 MNCs, MSD & Janssen grew at 6.9% and Ranbaxy at 5.7%
Under the Non-NLEM category Indian Companies degrew at 11.1% whereas MNCs degrew at 2.5%
DPCO V/s Non DPCO Market:
The DPCO 2013 containing molecules market was at –0.7% whereas the non DPCO market grew by 8.90% resulting in an overall growth of 7.2% for July 2014
NLEM Category showed positive unit growth at 3.2%
The DPCO 2013 portfolio for Pfizer degrew at 16.7%, GSK degrew at 7.9% & Ranbaxy grew by 18.2%.
Source: AIOCD Pharmasofttech AWACS
This document discusses several topics from the Torah portions of Behar and Bechukkotai:
1. The sabbatical year is meant to reflect that God is the ultimate owner of the land, not humans. It fosters a sense of serving God rather than selfish interests. Modern applications could include periodic sabbaticals from work or other spiritual renewal practices.
2. The blessings and curses described are meant for societies that broadly reject God's ways, not individuals. Living with God may spiritually bless people in intangible ways like strength and gratitude even during hard times. Rejecting God leaves one vulnerable without Divine support.
3. The book of Leviticus closes by discussing
1) The document provides an introduction and overview to the Torah portion of Mishpatim, which moves from narrative to God's instructions on how to live. It discusses themes around limiting personal power, boundaries, and early principles of law and ethics.
2) Key instructions and laws covered include slavery, killing, treatment of parents, kidnapping, harming others, compensation for injuries, theft, liability for damage, care of property, rituals, treatment of strangers/widows/orphans, loans, and festivals.
3) The overall messages conveyed encourage loyalty to God, fairness, limits on taking advantage of others, appreciation for blessings, and duties that extend from oneself to community.
Indian Pharma Market - Top 50 Ranking for Sep-2014Anup Soans
Indian Pharma Market (IPM) Key Insights for Sep 2014: IPM grew by 578 Crores over Aug 2014 & 1227 Crs over Sep 2013.
The Seasonal spike seen in 2012 from July onwards, which peaks in Sep/Oct and comes down in Nov, was not observed last year due to DPCO / NLEM issues. Hence we are entering a phase where on low base of last year, the growth rates are expected to be in strong double digits for the next 3-4 months.
Source: AIOCD Pharmasofttech AWACS
Major Highlights for Month of July 2014: IPM clocked 7161 Crs in July 2014
Indian Pharma Market grew at 7.2% for the month of July 2010
For the month of July 2014, among the top 10, Sun Pharma grew by 14.2%, Lupin by 13.2% & Cipla at 9.5%
Macleods grew at 27.9% to be the 10th biggest corporate for the month of July 2014
With the Portfolio of Elder, Torrent is now placed at 16th rank in IPM.
24 co's have crossed the growth of IPM for the month of July 2014 among top 50
Among the top 50 Co's, Akumentis has the highest growth of 49.0% followed by Ajanta at 41.2% & Apex at 40.9%
16 Co's showed double digit growths among the top 50
Among the 11-20 ranked co's Macleods has the highest growth of 27.9% followed by Ipca at 21.2% & Aristo at 16.2%
Among the 51-60 ranked co's, Panacea grows at 36.9% followed by Troikaa at 22.3 & Systopic 20.3%
Among the 61-75 ranked co's, Lincoln grew at 43.7% followed by Corona at 36.3% & Serdia at 19.6%
Indian V/S MNCs:
Indian companies have grown at 9.1% versus 1.5% for MNCs in July 2014
Among the top 50 MNCs, MSD & Janssen grew at 6.9% and Ranbaxy at 5.7%
Under the Non-NLEM category Indian Companies degrew at 11.1% whereas MNCs degrew at 2.5%
DPCO V/s Non DPCO Market:
The DPCO 2013 containing molecules market was at –0.7% whereas the non DPCO market grew by 8.90% resulting in an overall growth of 7.2% for July 2014
NLEM Category showed positive unit growth at 3.2%
The DPCO 2013 portfolio for Pfizer degrew at 16.7%, GSK degrew at 7.9% & Ranbaxy grew by 18.2%.
Source: AIOCD Pharmasofttech AWACS
This document discusses several topics from the Torah portions of Behar and Bechukkotai:
1. The sabbatical year is meant to reflect that God is the ultimate owner of the land, not humans. It fosters a sense of serving God rather than selfish interests. Modern applications could include periodic sabbaticals from work or other spiritual renewal practices.
2. The blessings and curses described are meant for societies that broadly reject God's ways, not individuals. Living with God may spiritually bless people in intangible ways like strength and gratitude even during hard times. Rejecting God leaves one vulnerable without Divine support.
3. The book of Leviticus closes by discussing
1) The document provides an introduction and overview to the Torah portion of Mishpatim, which moves from narrative to God's instructions on how to live. It discusses themes around limiting personal power, boundaries, and early principles of law and ethics.
2) Key instructions and laws covered include slavery, killing, treatment of parents, kidnapping, harming others, compensation for injuries, theft, liability for damage, care of property, rituals, treatment of strangers/widows/orphans, loans, and festivals.
3) The overall messages conveyed encourage loyalty to God, fairness, limits on taking advantage of others, appreciation for blessings, and duties that extend from oneself to community.
This document discusses several mitzvot related to justice found in the Torah. It begins by covering mitzvot about civil damages and liability, drawing parallels between Biblical rules and modern tort law concepts. It then discusses mitzvot governing commercial transactions and bailments. Finally, it examines mitzvot concerning proper conduct for kings and leaders, as well as for war. The document analyzes each mitzvah and explores broader ethical principles and duties that can be derived from them.
The document discusses finding meaning in ancient religious texts for modern diverse believers. It suggests that while some see religious rules as outdated, they were meant to provide divine guidance on living with others. To find relevant guidance today, believers must look past the ancient context and cultural details to uncover deeper meanings within the texts. The final paragraph quotes that the words are just a covering - the real purpose is the inner guidance and life lessons that can still apply today.
1. The passage discusses the first set of mitzvot (commandments) given by God to Moses regarding the Passover and Festival of Unleavened Bread. These serve to recall God's redemption from Egypt annually and establish a new beginning as God's people.
2. Specific mitzvot discussed include sharing a meal of the paschal lamb, putting blood on the doorposts, eating unleavened bread, and not leaving leftovers. Symbolic meanings are given for each ritual element.
3. The passage acknowledges the complexity of understanding the 10th plague of the firstborn in Egypt from a modern perspective, noting God's mystery, the severity of Pharaoh's tyranny, and pain it caused
This document provides information on biomarkers from GVK BIO's Clinical Biomarker Database (GOBIOM). It summarizes the types and numbers of biomarkers in the database categorized by indication, therapeutic area, specimen, and biomarker qualification. The largest numbers of biomarkers are for oncology and diseases of the circulatory system. Biomarkers are also categorized by their use for efficacy, diagnosis, safety, and other purposes. GOBIOM contains over 22,000 biomarkers and is being licensed by the US FDA to aid in their biomarker qualification process.
This document provides an analysis and discussion of the biblical text Haazinu. It examines various passages from the text, discussing imagery of water, God caring for the Israelites like an eagle cares for its young, and warnings against worshipping false gods. The analysis notes how Moses wants to draw the people's minds to past redemption and calls them to faithfully observe God's teachings for long life in the promised land. While containing warnings, the text also conveys hopeful themes through Moses' words to be taken to heart by future generations.
The document summarizes GVK BIO Informatics, which provides complete informatics solutions from knowledge management to predictive analytics. It highlights key databases and tools developed by GVK including CTOD (Clinical Trial Outcome Database) and a biomarker database. It also describes GVK's knowledge base development through custom data curation for leading database providers and key publications utilizing GVK's GOSTAR database.
GVK BIO is one of the largest India-based Discovery, Development and Manufacturing solutions provider to the Biopharma industry. GVK BIO provides a continuum of Drug
Discovery solutions from pre-Hit to candidate
selection. Our expertise spans across
numerous therapeutic areas with a focus on
Oncology, Pain and Metabolic diseases. We
leverage our expertise in Chemistry, Biology,
CADD, ADMET/PK and Animal Disease models
to provide a customised and truly integrated
model for Drug Discovery leading to preclinical
candidates.
Lung Fibrosis Model Representative Studies by Aragen BioscienceGVK Biosciences
Aragen Bioscience is a contract research organization that offers a range of in vitro and in vivo research services including protein production, antibody discovery, stable cell line development, and preclinical testing. They have 25,000 square feet of laboratory space in the San Francisco Bay Area and a team of highly skilled scientists, most holding PhDs. The document then describes a bleomycin-induced lung fibrosis mouse model where bleomycin is administered to induce pulmonary fibrosis over 2-3 weeks. Outcome measures include body weight, lung weight, BAL cell counts, and histopathology. Pirfenidone is presented as a positive control, showing it can partially rescue body weight loss and reduce lung weight and BAL cell infiltration compared to bleomycin alone
GVK Biosciences (GVK BIO) Clinical Research division has an independent Quality Assurance (QA) unit which conducts audits of services of all business lines within the division on a routine basis to ensure delivery of quality services. The Clinical Research QA staff report
to the Director-QA, GVK BIO who in turn reports to the CEO of GVK BIO
Project Management at GVK BIO is led by skilled and highly motivated executives with experience averaging 6-7 years. Our Project Managers (PMs) employ proven planning, time management, problem solving and communication skills to ensure timely project delivery,
determined to exceed customer expectations.
GVK BIO vivarium is AAALAC certified and registered with CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals), Government of India.
The Medical Affairs team at GVK Biosciences (GVK BIO) comprises of well trained medical professionals with cumulative Clinical Research experience of about 28 years.
At GVK BIO, seamless integration of life sciences expertise with information technology helps bring database products and services to accelerate your research from discovery to development.
This short document appears to contain numerical values, including the numbers 6.1, 20, and 17, but provides no other context or explanation. It is unclear what these numbers represent or what the overall topic or purpose of the document is based on the limited information given.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
BioIT converts information to knowledge for usage in Discovery & Development. It integrates data from multidisciplinary areas using Science and Information Technology
At GVK BIO, we provide a full range of analytical services from Discovery to Commercial Phase III. The Analytical Service portfolio includes method development and validation, stability studies, analytical testing and release, structure elucidation, GMP separation and CMC Support
GVK BIO offers a range of in vitro ADME screening services including assays to study metabolism, distribution, toxicity, permeability, solubility, and physicochemical properties of compounds. Their capabilities include studies of physicochemical properties, absorption and distribution, metabolism and excretion, protein binding, and metabolite identification. They use techniques such as Log D/Log P determination, solubility assessment, Caco-2 and PAMPA permeability assays, microsomal and hepatocyte stability assays, and CYP inhibition assays to provide comprehensive data to evaluate compound properties.
This document discusses several mitzvot related to justice found in the Torah. It begins by covering mitzvot about civil damages and liability, drawing parallels between Biblical rules and modern tort law concepts. It then discusses mitzvot governing commercial transactions and bailments. Finally, it examines mitzvot concerning proper conduct for kings and leaders, as well as for war. The document analyzes each mitzvah and explores broader ethical principles and duties that can be derived from them.
The document discusses finding meaning in ancient religious texts for modern diverse believers. It suggests that while some see religious rules as outdated, they were meant to provide divine guidance on living with others. To find relevant guidance today, believers must look past the ancient context and cultural details to uncover deeper meanings within the texts. The final paragraph quotes that the words are just a covering - the real purpose is the inner guidance and life lessons that can still apply today.
1. The passage discusses the first set of mitzvot (commandments) given by God to Moses regarding the Passover and Festival of Unleavened Bread. These serve to recall God's redemption from Egypt annually and establish a new beginning as God's people.
2. Specific mitzvot discussed include sharing a meal of the paschal lamb, putting blood on the doorposts, eating unleavened bread, and not leaving leftovers. Symbolic meanings are given for each ritual element.
3. The passage acknowledges the complexity of understanding the 10th plague of the firstborn in Egypt from a modern perspective, noting God's mystery, the severity of Pharaoh's tyranny, and pain it caused
This document provides information on biomarkers from GVK BIO's Clinical Biomarker Database (GOBIOM). It summarizes the types and numbers of biomarkers in the database categorized by indication, therapeutic area, specimen, and biomarker qualification. The largest numbers of biomarkers are for oncology and diseases of the circulatory system. Biomarkers are also categorized by their use for efficacy, diagnosis, safety, and other purposes. GOBIOM contains over 22,000 biomarkers and is being licensed by the US FDA to aid in their biomarker qualification process.
This document provides an analysis and discussion of the biblical text Haazinu. It examines various passages from the text, discussing imagery of water, God caring for the Israelites like an eagle cares for its young, and warnings against worshipping false gods. The analysis notes how Moses wants to draw the people's minds to past redemption and calls them to faithfully observe God's teachings for long life in the promised land. While containing warnings, the text also conveys hopeful themes through Moses' words to be taken to heart by future generations.
The document summarizes GVK BIO Informatics, which provides complete informatics solutions from knowledge management to predictive analytics. It highlights key databases and tools developed by GVK including CTOD (Clinical Trial Outcome Database) and a biomarker database. It also describes GVK's knowledge base development through custom data curation for leading database providers and key publications utilizing GVK's GOSTAR database.
GVK BIO is one of the largest India-based Discovery, Development and Manufacturing solutions provider to the Biopharma industry. GVK BIO provides a continuum of Drug
Discovery solutions from pre-Hit to candidate
selection. Our expertise spans across
numerous therapeutic areas with a focus on
Oncology, Pain and Metabolic diseases. We
leverage our expertise in Chemistry, Biology,
CADD, ADMET/PK and Animal Disease models
to provide a customised and truly integrated
model for Drug Discovery leading to preclinical
candidates.
Lung Fibrosis Model Representative Studies by Aragen BioscienceGVK Biosciences
Aragen Bioscience is a contract research organization that offers a range of in vitro and in vivo research services including protein production, antibody discovery, stable cell line development, and preclinical testing. They have 25,000 square feet of laboratory space in the San Francisco Bay Area and a team of highly skilled scientists, most holding PhDs. The document then describes a bleomycin-induced lung fibrosis mouse model where bleomycin is administered to induce pulmonary fibrosis over 2-3 weeks. Outcome measures include body weight, lung weight, BAL cell counts, and histopathology. Pirfenidone is presented as a positive control, showing it can partially rescue body weight loss and reduce lung weight and BAL cell infiltration compared to bleomycin alone
GVK Biosciences (GVK BIO) Clinical Research division has an independent Quality Assurance (QA) unit which conducts audits of services of all business lines within the division on a routine basis to ensure delivery of quality services. The Clinical Research QA staff report
to the Director-QA, GVK BIO who in turn reports to the CEO of GVK BIO
Project Management at GVK BIO is led by skilled and highly motivated executives with experience averaging 6-7 years. Our Project Managers (PMs) employ proven planning, time management, problem solving and communication skills to ensure timely project delivery,
determined to exceed customer expectations.
GVK BIO vivarium is AAALAC certified and registered with CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals), Government of India.
The Medical Affairs team at GVK Biosciences (GVK BIO) comprises of well trained medical professionals with cumulative Clinical Research experience of about 28 years.
At GVK BIO, seamless integration of life sciences expertise with information technology helps bring database products and services to accelerate your research from discovery to development.
This short document appears to contain numerical values, including the numbers 6.1, 20, and 17, but provides no other context or explanation. It is unclear what these numbers represent or what the overall topic or purpose of the document is based on the limited information given.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
BioIT converts information to knowledge for usage in Discovery & Development. It integrates data from multidisciplinary areas using Science and Information Technology
At GVK BIO, we provide a full range of analytical services from Discovery to Commercial Phase III. The Analytical Service portfolio includes method development and validation, stability studies, analytical testing and release, structure elucidation, GMP separation and CMC Support
GVK BIO offers a range of in vitro ADME screening services including assays to study metabolism, distribution, toxicity, permeability, solubility, and physicochemical properties of compounds. Their capabilities include studies of physicochemical properties, absorption and distribution, metabolism and excretion, protein binding, and metabolite identification. They use techniques such as Log D/Log P determination, solubility assessment, Caco-2 and PAMPA permeability assays, microsomal and hepatocyte stability assays, and CYP inhibition assays to provide comprehensive data to evaluate compound properties.
This document lists 14 intermediates used in pharmaceutical manufacturing along with their CAS numbers. The intermediates include carvedilol, ezetimibe, fluvastatin sodium, lamotrigine, lansoprazole, montelukast sodium, and zoipidem hemitartrate. Information provided includes the name of each intermediate, its corresponding CAS number, and in some cases additional chemical identifiers. The intermediates support the production of various active pharmaceutical ingredients.